Mensia
Technologies, french MedTech start up, leads the new booming
category of Digital therapeutics with its revolutionary « at home «
neurofeedback, to train the brain and cure neuropsy disorders without
drugs.
Co-founder INRIA-IT2,
existing shareholders and now HARA,
which are business angels experts in medical device category, joined
this fund raise. BPI
de Rennes is also part of this tour.
Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in
Rennes are computing real time signaling softwares. The neurofeedback
technique is non invasive, at home and without drugs. MENSIA
KOALA treats ADHD, Attention Deficit Disorders with or without
Hyperactivity, children and adolescents. This unique medical device is a
therapeutic video game on an interactive tablet connected to the brain
activity. Children learn to control their attention by exercising 3
times a week during 4 months of treatment. Visual feedback given during
the game, allows the children to learn, control and create automatisms.
Six years of R&D with 12 $millions invested, including the last largest
clinical multicentric trial never ever made, NEWROFEED-Koala,
successfuly lead to the grant of a CE mark class IIa in Europe. Kick
start of the sales in March for France.
37 health points of care
from french national partner HOMEPERF,
delivers family training for home use of Koala. The device is prescribed
and ordered directly on the website. Family received their Mensia Koala
at home : all items ready to use for 4 month treatment, with webportail
supervision. Children benefit from significant reduction of their
attention deficit and or hyperactivity with long lasting effects.
Benefit/Risk ratio is extremely favorable and no adverse event compared
to the amphetamines drugs (Ritaline).
Michel du Peloux, CEO of Mensia Technologies : « We are proud to deliver the first worldwide digital therapeutic device to treat ADHD with a Class IIa registration for medical scripts and follow up all over Europe. Far from neurogaming, we have 5 patents, randomised clinical trials and state of the art expertise in brain computer interface. Our pipeline of « at home neurofeedback » is promising : resistant chronic low back pain despite opiods, is our next medical device. Mensia Technologies initiates now the next tour for a serie A of 20 M$ aiming to the USA deployement.
About Mensia Technologies : https://www.mensia.com
About
Mensia Koala : https://www.mensia-koala.com,
About
HARA : http://health-angels-ra.com/actualites/
About
clinical study : http://www.newrofeed.com/
About
INRIA : http://it-translation.fr/projets/fonds/
About
BPI Rennes : https://www.bpifrance.fr/Contactez-nous/Direction-regionale-Rennes
View source version on businesswire.com: https://www.businesswire.com/news/home/20180621005925/en/
Mensia Technologies
Michel du Peloux
00 (33)6 24 34 10 61
mdp@mensiatech.com
or
Press
contact : RPCA
Nathalie Chrysafis & Carole Bernardin
00
(33)1 42 30 81 00
n.chrysafis@rpca.fr
c.bernardin@rpca.fr
Permalink: http://www.businesswire.com/news/home/20180621005925/en
